Literature DB >> 12584269

Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.

Finn Thomsen Nielsen1, Peter Ottosen, Henrik Starklint, Hans Dieperink.   

Abstract

BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation. These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open. In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described. The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.
METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats. In the 'conscious catheterized rat' model, the glomerular filtration rate (GFR) was measured as the clearance of Cr(EDTA). The morphological analysis of the kidneys included a semi-quantitative scoring system analysing the degree of striped fibrosis, subcapsular fibrosis and the number of basophilic tubules, plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red.
RESULTS: CsA, FK506 and SRL all significantly decreased the GFR. A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances. The morphological changes presented a similar pattern. The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02). The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).
CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584269     DOI: 10.1093/ndt/18.3.491

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

1.  Knockdown of core 1 beta 1, 3-galactosyltransferase prolongs skin allograft survival with induction of galectin-1 secretion and suppression of CD8+ T cells: T synthase knockdown effects on galectin-1 and CD8+ T cells.

Authors:  Hai-Dan Chen; Xia Zhou; Gang Yu; Ying-Lan Zhao; Yushan Ren; Yi-Dan Zhou; Qiao Li; Xiao-Lian Zhang
Journal:  J Clin Immunol       Date:  2012-03-06       Impact factor: 8.317

Review 2.  Benefit-risk assessment of sirolimus in renal transplantation.

Authors:  Dirk R J Kuypers
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Tacrolimus-Eluting Disk within the Allograft Enables Vascularized Composite Allograft Survival with Site-Specific Immunosuppression without Systemic Toxicity.

Authors:  Raman Venkataramanan; Alexander M Spiess; Firuz G Feturi; Jignesh V Unadkat; Wensheng Zhang; Mohamed El Hag; Yong Wang; Chiaki Komatsu; Damian Grybowski; Zhaoxiang Zhang; Vasil Erbas; Huseyin Sahin; Sean Mcclaine; Sinan Oksuz; Jan Plock; Vijay S Gorantla; Kia M Washington; Mario G Solari
Journal:  Pharm Res       Date:  2022-08-02       Impact factor: 4.580

4.  Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function.

Authors:  Jost Klawitter; Jamie Bendrick-Peart; Birgit Rudolph; Virginia Beckey; Jelena Klawitter; Manuel Haschke; Christopher Rivard; Laurence Chan; Dieter Leibfritz; Uwe Christians; Volker Schmitz
Journal:  Chem Res Toxicol       Date:  2009-01       Impact factor: 3.739

5.  Evolution of β-Cell Replacement Therapy in Diabetes Mellitus: Islet Cell Transplantation.

Authors:  Cyrus Jahansouz; Cameron Jahansouz; Sean C Kumer; Kenneth L Brayman
Journal:  J Transplant       Date:  2011-10-15

6.  Sirolimus enhances cyclosporine a-induced cytotoxicity in human renal glomerular mesangial cells.

Authors:  Séin O'Connell; Craig Slattery; Michael P Ryan; Tara McMorrow
Journal:  J Transplant       Date:  2012-01-23

7.  Comparison of early and late conversion of sirolimus in experimental model of chronic cyclosporine nephropathy.

Authors:  Jin Young Kim; Jung Yeon Ghee; Sun Woo Lim; Shang Guo Piao; Byung Ha Chung; Hye Eun Yoon; Hyeon Seok Hwang; Bum Soon Choi; Jin Kim; Chul Woo Yang
Journal:  J Korean Med Sci       Date:  2012-01-27       Impact factor: 2.153

8.  The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity.

Authors:  Finn Thomsen Nielsen; Boye L Jensen; Pernille B L Hansen; Niels Marcussen; Peter Bie
Journal:  BMC Nephrol       Date:  2013-02-20       Impact factor: 2.388

Review 9.  Benefit-risk assessment of ciclosporin withdrawal in renal transplant recipients.

Authors:  Eric Thervet; Frank Martinez; Christophe Legendre
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

Review 10.  Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.

Authors:  Eric Thervet
Journal:  Int J Nanomedicine       Date:  2006
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.